Article Sidebar

PDF
Date Published: 19/02/2023
Abstract Views: 223
Views PDF: 134
DOI: https://doi.org/10.51298/vmj.v522i1.4226
Issue
Vol. 522 No. 1 (2023)
Section
Các bài báo
How to Cite
Đỗ, H. K., & Nguyễn, V. T. (2023). PRELIMINARY RESULTS OF NON-SMALL CELL LUNG CANCER ACQUIRED RESISTED TO EGFR TKIS FIRST - AND SECOND-GENERATIONS WITHOUT PRESENCE OF T790M MUTATION. Vietnam Medical Journal, 522(1). https://doi.org/10.51298/vmj.v522i1.4226

PRELIMINARY RESULTS OF NON-SMALL CELL LUNG CANCER ACQUIRED RESISTED TO EGFR TKIS FIRST - AND SECOND-GENERATIONS WITHOUT PRESENCE OF T790M MUTATION

Hùng Kiên Đỗ1,, Văn Tài Nguyễn1
1 National Cancer Hospital

Main Article Content

Abstract

Objective: Evaluating the response rates and analyzing affected factors to response rate of paclitaxel – cisplatin chemotherapy for the treatment of advanced/ metastatic non-small cell lung cancer acquired resistance to EGFR TKIs first- and second-generations without presence of T790M mutation at National Cancer Hospital from 01/2017 to 05/2022. Patients and method: Retrospective and prospective analysis of 55 patients with advanced/ metastatic non-small cell lung carcinoma acquired resistance to EGFR TKIs first- and second-generations without presence of T790M mutation at National Cancer Hospital from 01/2017 to 05/2022. Results: Most of patients were received of 100% full-dose chemotherapy. Mean cycles were 5.7. Of 55 patients, 26 achieved a partial response (47,3%), no complet response was observed. Disease control rate was 74.5%. performance status ECOG 0 had a higher response rate compared to ECOG 1. Symptoms relief was reported in 63.6% patient with chemotherapy. Conclusion: Paclitaxel – carboplatin chemotherapy is an appropriate regimen choice for patients with non-small cell lung cancer after acquired resistance to tyrosine kinase without presence of T790M mutation.

Article Details

Keywords

Non-small cell lung cancer, paclitaxel-carboplatin, acquired resistance to TKIs

References

1. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA. Cancer J. Clin. 2021, 71, 209–249, doi:10.3322/ caac.21660.
2. Davis, F.; Dolecek, T.; Mccarthy, B.; Villano, J. Toward Determining the Lifetime Occurrence of Metastatic Brain Tumors Estimated from 2007 United States Cancer Incidence Data. Neuro-Oncol. 2012, 14, 1171–1177, doi:10.1093/neuonc/nos152.
3. Rosell, R.; Carcereny, E.; Gervais, R.; Vergnenegre, A.; Massuti, B.; Felip, E.; Palmero, R.; Garcia-Gomez, R.; Pallares, C.; Sanchez, J.M.; et al. Erlotinib versus Standard Chemotherapy as First-Line Treatment for European Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer (EURTAC): A Multicentre, Open-Label, Randomised Phase 3 Trial. Lancet Oncol. 2012, 13, 239–255, doi:10.1016/S1470-2045(11)70393-X.
4. Mok, T.S.; Wu, Y.-L.; Thongprasert, S.; Yang, C.-H.; Chu, D.-T.; Saijo, N.; Sunpaweravong, P.; Han, B.; Margono, B.; Ichinose, Y.; et al. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma. N. Engl. J. Med. 2009, 361, 947–957, doi:10.1056/NEJMoa0810699.
5. Sequist, L.V.; Yang, J.C.-H.; Yamamoto, N.; O’Byrne, K.; Hirsh, V.; Mok, T.; Geater, S.L.; Orlov, S.; Tsai, C.-M.; Boyer, M.; et al. Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations. J. Clin. Oncol. 2013, 31, 3327–3334, doi:10.1200/JCO.2012.44.2806.
6. Mok, T.S.; Wu, Y.-L.; Ahn, M.-J.; Garassino, M.C.; Kim, H.R.; Ramalingam, S.S.; Shepherd, F.A.; He, Y.; Akamatsu, H.; Theelen, W.S.M.E.; et al. Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer. N. Engl. J. Med. 2017, 376, 629–640, doi:10.1056/NEJMoa1612674.
7. Metro, G.; Chiari, R.; Mare, M.; Giannarelli, D.; Tofanetti, F.R.; Minotti, V.; Ferraldeschi, M.; Giuffrida, D.; Marcomigni, L.; Bennati, C.; et al. Carboplatin plus Pemetrexed for Platinum-Pretreated, Advanced Non-Small Cell Lung Cancer: A Retrospective Study with Pharmacogenetic Evaluation. Cancer Chemother. Pharmacol. 2011, 68, 1405–1412, doi:10.1007/s00280-011-1632-x.
8. Scagliotti, G.V. Pemetrexed plus Carboplatin or Oxaliplatin in Advanced Non-Small Cell Lung Cancer. Sel. Proc. Fromthe Chemother. Found. Symp. Innov. Cancer Ther. Tomorrow 2005, 32, S5–S8, doi:10.1053/ j.seminoncol.2005.02.006.
9. Rosell, R.; Gatzemeier, U.; Betticher, D.C.; Keppler, U.; Macha, H.N.; Pirker, R.; Berthet, P.; Breau, J.L.; Lianes, P.; Nicholson, M.; et al. Phase III Randomised Trial Comparing Paclitaxel/Carboplatin with Paclitaxel/Cisplatin in Patients with Advanced Non-Small-Cell Lung Cancer: A Cooperative Multinational Trial. Ann. Oncol. 2002, 13, 1539–1549, doi:10.1093/annonc/mdf332.
10. Sandler, A.; Gray, R.; Perry, M.C.; Brahmer, J.; Schiller, J.H.; Dowlati, A.; Lilenbaum, R.; Johnson, D.H. Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer. N. Engl. J. Med. 2006, 355, 2542–2550, doi:10.1056/NEJMoa061884.